Google’s AI genome tech could revolutionise cancer treatment – if the NHS can figure out how to actually deploy it
A ground-breaking AI model from Google DeepMind is poised to transform our understanding of the human genome and accelerate personalised cancer therapies.
But a new UK parliamentary inquiry highlights the stark reality: the National Health Service (NHS) often struggles to turn such cutting-edge innovations into routine patient care.
The House of Lords Science and Technology Committee launched an inquiry on Monday (9 March) titled “Innovation in the NHS: personalised medicine and AI.”
It spotlights advances in genomics and AI as prime examples of promising UK-linked life sciences developments that frequently fail to reach widespread NHS adoption.
Central to the discussion is Google’s AlphaGenome, an AI tool developed by DeepMind that can analyse vast stretches of DNA code, up to a million letters at once.
Released earlier this year, AlphaGenome predicts how genetic variations influence health, pinpointing mutations that drive diseases like cancer while distinguishing them from harmless ones.
Researchers have already applied AlphaGenome to identify cancer-fueling mutations and potential treatment targets. For instance, it has helped elucidate mechanisms in cancers such as T-cell acute lymphoblastic leukemia by linking non-coding DNA changes to disease-causing gene activation.
Experts describe it as a major milestone that could speed up genomic medicine, automate complex data analysis, and support truly personalised treatments tailored to a patient’s unique genetic profile.
Such tools align with therapies like CAR T-cell treatments, where a patient’s immune cells are genetically modified to attack cancer. These individualized approaches offer life-saving potential for certain blood cancers and solid tumors, but they remain expensive and logistically challenging to scale.
“Advances in AI and genomics are creating the prospect of truly personalised medicine across prevention, diagnosis and treatment,” said Lord Mair CBE, Chair of the Committee.
“Our inquiry will use personalised medicine as a case study to explore a broader question: why does the NHS struggle to adopt the UK’s cutting-edge life sciences innovations, and what could be done to fix that?”
Systemic barriers
The inquiry points to systemic barriers hindering deployment:
- Fragmented NHS structure leading to uneven access across regions and trusts.
- Procurement processes, clinical pathways, and regulatory hurdles that slow progress from research to bedside.
- High costs of personalized treatments, which require individual tailoring.
- Gaps in infrastructure, including clinical trials, academic support, and feedback loops between researchers, industry, and the health service.
The announcement specifically references AlphaGenome as an example of novel AI offering hope for advancing genomic medicine by improving understanding of genetic effects and automating analysis for personalized drugs.
It ties into broader government ambitions, such as the AI for Science strategy aiming to deliver trial-ready drugs in just 100 days by 2030.
Yet the inquiry underscores a persistent translation gap. While the UK excels in early-stage research, bolstered by institutions like DeepMind, the jump to NHS-wide delivery remains blocked.
Personalised therapies like gene-edited treatments could revolutionise cancer care, but without addressing these blockages, patients may wait years for benefits.
